Cargando…
In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis
The host defense derived peptide was assessed in different model systems with increasing complexity employing the highly aggressive NRAS mutated melanoma metastases cell line MUG-Mel2. Amongst others, fluorescence microscopy and spectroscopy, as well as cell death studies were applied for liposomal,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687695/ https://www.ncbi.nlm.nih.gov/pubmed/36428530 http://dx.doi.org/10.3390/biomedicines10112961 |
_version_ | 1784836073127411712 |
---|---|
author | Wußmann, Maximiliane Groeber-Becker, Florian Kai Riedl, Sabrina Alihodzic, Dina Padaric, Daniel Gerlitz, Lisa Stallinger, Alexander Liegl-Atzwanger, Bernadette Zweytick, Dagmar Rinner, Beate |
author_facet | Wußmann, Maximiliane Groeber-Becker, Florian Kai Riedl, Sabrina Alihodzic, Dina Padaric, Daniel Gerlitz, Lisa Stallinger, Alexander Liegl-Atzwanger, Bernadette Zweytick, Dagmar Rinner, Beate |
author_sort | Wußmann, Maximiliane |
collection | PubMed |
description | The host defense derived peptide was assessed in different model systems with increasing complexity employing the highly aggressive NRAS mutated melanoma metastases cell line MUG-Mel2. Amongst others, fluorescence microscopy and spectroscopy, as well as cell death studies were applied for liposomal, 2D and 3D in vitro models including tumor spheroids without or within skin models and in vivo mouse xenografts. Summarized, MUG-Mel2 cells were shown to significantly expose the negatively charged lipid phosphatidylserine on their plasma membranes, showing they are successfully targeted by RDP22. The peptide was able to induce cell death in MUG-Mel2 2D and 3D cultures, where it was able to kill tumor cells even inside the core of tumor spheroids or inside a melanoma organotypic model. In vitro studies indicated cell death by apoptosis upon peptide treatment with an LC(50) of 8.5 µM and seven-fold specificity for the melanoma cell line MUG-Mel2 over normal dermal fibroblasts. In vivo studies in mice xenografts revealed effective tumor regression upon intratumoral peptide injection, indicated by the strong clearance of pigmented tumor cells and tremendous reduction in tumor size and proliferation, which was determined histologically. The peptide RDP22 has clearly shown high potential against the melanoma cell line MUG-Mel2 in vitro and in vivo. |
format | Online Article Text |
id | pubmed-9687695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96876952022-11-25 In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis Wußmann, Maximiliane Groeber-Becker, Florian Kai Riedl, Sabrina Alihodzic, Dina Padaric, Daniel Gerlitz, Lisa Stallinger, Alexander Liegl-Atzwanger, Bernadette Zweytick, Dagmar Rinner, Beate Biomedicines Article The host defense derived peptide was assessed in different model systems with increasing complexity employing the highly aggressive NRAS mutated melanoma metastases cell line MUG-Mel2. Amongst others, fluorescence microscopy and spectroscopy, as well as cell death studies were applied for liposomal, 2D and 3D in vitro models including tumor spheroids without or within skin models and in vivo mouse xenografts. Summarized, MUG-Mel2 cells were shown to significantly expose the negatively charged lipid phosphatidylserine on their plasma membranes, showing they are successfully targeted by RDP22. The peptide was able to induce cell death in MUG-Mel2 2D and 3D cultures, where it was able to kill tumor cells even inside the core of tumor spheroids or inside a melanoma organotypic model. In vitro studies indicated cell death by apoptosis upon peptide treatment with an LC(50) of 8.5 µM and seven-fold specificity for the melanoma cell line MUG-Mel2 over normal dermal fibroblasts. In vivo studies in mice xenografts revealed effective tumor regression upon intratumoral peptide injection, indicated by the strong clearance of pigmented tumor cells and tremendous reduction in tumor size and proliferation, which was determined histologically. The peptide RDP22 has clearly shown high potential against the melanoma cell line MUG-Mel2 in vitro and in vivo. MDPI 2022-11-17 /pmc/articles/PMC9687695/ /pubmed/36428530 http://dx.doi.org/10.3390/biomedicines10112961 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wußmann, Maximiliane Groeber-Becker, Florian Kai Riedl, Sabrina Alihodzic, Dina Padaric, Daniel Gerlitz, Lisa Stallinger, Alexander Liegl-Atzwanger, Bernadette Zweytick, Dagmar Rinner, Beate In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis |
title | In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis |
title_full | In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis |
title_fullStr | In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis |
title_full_unstemmed | In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis |
title_short | In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis |
title_sort | in model, in vitro and in vivo killing efficacy of antitumor peptide rdp22 on mug-mel2, a patient derived cell line of an aggressive melanoma metastasis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687695/ https://www.ncbi.nlm.nih.gov/pubmed/36428530 http://dx.doi.org/10.3390/biomedicines10112961 |
work_keys_str_mv | AT wußmannmaximiliane inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis AT groeberbeckerfloriankai inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis AT riedlsabrina inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis AT alihodzicdina inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis AT padaricdaniel inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis AT gerlitzlisa inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis AT stallingeralexander inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis AT lieglatzwangerbernadette inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis AT zweytickdagmar inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis AT rinnerbeate inmodelinvitroandinvivokillingefficacyofantitumorpeptiderdp22onmugmel2apatientderivedcelllineofanaggressivemelanomametastasis |